85-3713-67　Letrozole 5g　CAS No:112809-51-5　281225

特徴

• A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic. An orally bioavailable non-steroidal triazole compound that acts as a potent and selective inhibitor of aromatase (IC50=140, 350 and 450pM in Dex-treated fibroblasts, MCF-7Ca, and JEG-3 cells, respectively). Competitively, but reversibly binds to the heme iron of aromatase. Does not affect the synthesis of adrenal mineralocorticoid or glucocorticoids. Reported to be highly effective as an anti-estrogenic and anti-proliferative agent in estrogen-rich tumors. Also delays the fusing of the growth plates in adolescents and enhances the effectiveness of growth hormone. Shown to synergistically induce apoptosis and cause tumor regression when combined with IGF-1R inhibitors.
• Synonyms:4,4’-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile; 4-[1-(4-Cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile; CGS 20267; Femara; Lerozole; Letrazole; Aromatase Inhibitor II
• Molecular Formula:C17H11N5
• Molecular Weight:285.30
• Appearance:Supplied as a white to off-white solid.
• Purity:≥98%
• Water (KF):≤0.5%
• 1H-NMR:Corresponds to reference spectra
• FT-IR Spectrum:Corresponds to structure
• 13C-NMR:Corresponds to structure
• Storage and Stability:May be stored at RT for short-term only. Long-term storage is recommended at 4°C. Stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap.